RobertT.MorrisMD

Obstetrics & Gynecology • Detroit, MI

Gynecologic Oncology

Professor and Director, Division of Gynecologic Oncology, Wayne State University

Join to view full profile

Dr. Morris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Morris' full profile

Already have an account?

Office
4100 John R
Karmanos Cancer Center
Detroit, MI 48201
Phone+1 800-527-6266

Fax+1 313-576-8486

Education & Training

Detroit Medical Center/Wayne State UniversityResidency, Obstetrics and Gynecology, 1988 - 1994
University of Minnesota Medical SchoolClass of 1988

Certifications & Licensure

NV State Medical License Current
MI State Medical License 1989 - 2026
TX State Medical License 1994 - 1997
ME State Medical License Active through 1966
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Super Doctor SuperDoctors.com
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer Start of enrollment: 2004 Feb 01
Completed
Phase 2
Tissue Bank of Biological Specimens From Patients With Gynecologic Disease Start of enrollment: 2006 Mar 01
Unknown status
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
ACTIVE_NOT_RECRUITING
PHASE3
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Start of enrollment: 2012 Jul 02
Active, not recruiting
Phase 2
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Start of enrollment: 2013 May 08
COMPLETED
PHASE2
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2014 Jul 21
ACTIVE_NOT_RECRUITING
PHASE2
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients with Cervical Carcinoma Start of enrollment: 2017 Jun 22
ACTIVE_NOT_RECRUITING
PHASE2
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) Start of enrollment: 2022 Aug 31
RECRUITING
PHASE3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Attenuated titin protein expression is associated with advanced stages of ovarian cancer.
Harvey Sharma, Jaskaran Aujla, Asad Nawaz, Thabet Khasawneh, Ayesha Alvero
Molecular Therapy. Oncology. 2025-03-20
Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.
Ayesha B Alvero, Sharon Wu, Alex Farrell, Seongho Kim, John J Wallbillich
Gynecologic Oncology. 2025-02-18
Disparities in contemporary human papilloma virus vaccination uptake among adult women living in the United States: An All of Us Research Program study.
Terrence Y Wong, Nicholas K Adzibolosu, Larissa H Mattei, Alicia C Speak, Robert T Morris
Gynecologic Oncology. 2024-12-01